NCT03287765View on ClinicalTrials.gov

Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans

CompletedOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 31, 2021

Study Completion Date

July 19, 2021

Conditions
Alzheimer Disease
Interventions
DRUG

18F-AV-1451

Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Tammie L. S. Benzinger, MD, PhD

OTHER

NCT03287765 - Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans | Biotech Hunter | Biotech Hunter